Research progress of medication treatment of dry age-related macular degeneration
10.3980/j.issn.1672-5123.2023.11.13
- VernacularTitle:干性年龄相关性黄斑变性药物治疗研究进展
- Author:
Jie ZHOU
1
,
2
;
Qian-Yin CHEN
1
,
2
;
Jing-Lin ZHANG
1
,
2
Author Information
1. Aier School of Ophthalmology, Central South University, Changsha 410000, Hunan Province, China
2. Guangzhou Aier Eye Hospital, Guangzhou 510000, Guangdong Province, China
- Publication Type:Journal Article
- Keywords:
dry age-related macular degeneration;
geographic atrophy;
complement therapy;
antioxidant therapy;
drug therapy
- From:
International Eye Science
2023;23(11):1835-1839
- CountryChina
- Language:Chinese
-
Abstract:
Age-related macular degeneration(ARMD)is one of the leading causes of irreversible visual impairment worldwide, and the number of patients is increasing with the aging of the population, with dry ARMD accounting for about 90% of cases. Effective treatments for dry ARMD are currently lacking, making it a prominent area of research. Pharmacotherapy, targeting pathogenic factors such as oxidative damage, inflammation, and vascular issues contributing to ARMD, is one of the main treatments and some drugs have been shown to slow the progression of ARMD. This article reviews drug treatments for dry ARMD, including antioxidant drugs, complement biological agents, non-steroidal anti-inflammatory drugs and immunosuppressants, vasodilators, neurotrophic drugs, as well as traditional Chinese medicine. It summarizes their mechanisms and recent clinical research to contribute valuable insights for the treatment of dry ARMD and the development of novel therapeutic agents.
